Inflammation-Mediated Damage as a Potential Therapeutic Target in Acute Ischemic Stroke

摘要: Stroke represents worldwide one of the leading medical problems but acute treatment this condition remains challenging as no single drug has unequivocally demonstrated to be effective (Adams et al. 1994; The European Ad Hoc Consensus Group 1996). Intravenous thrombolysis with rt-PA is only FDA-approved therapy for stroke during first 3 h after clinical onset. Recently, health authorities have also approved its use in Union patients symptoms lasting more than h. However, majority receive neurological attention at a longer delay from symptom onset, epidemiological impact stage marginal.